The partnership will provide plan members with access to digital services aimed at older patients.
DarioHealth Corp signed a new contract with a national Medicare Advantage health plan. Dario is global digital health market company, and this contract will allow both companies to provide Plan members with Dario’s behavioral health solution, Twill. According to a press release, Dario was selected because its AI-based network has the opportunity to provide elder plan members with access to digital tools that will address broad emotional health and well-being services.
In a press release, Dario’s chief commercial officer Steven Nelson said, “There is a misconception that seniors will not engage with digital health, but our data tells us that is just a myth. Pre-Twill, the senior population on the Dario's platform was roughly 30%, a number that will expand with this partnership. The high comorbidity rate between metabolic and mental health conditions is something that Dario is prepared to address upon expansion of this partnership down the road. Seniors will engage with solutions that are tailored and relevant to their unique needs, and we've proven this across behavioral health and chronic health needs. We are excited about the momentum of our B2B2C core channel to health plans and employers."
Nelson continued, "The addition of another national health plan to our client base provides significant opportunity for revenue expansion and allows us to implement our newly refined enrollment and engagement technologies into a wider population of members. We believe that our comprehensive product offering not only helps secure more revenue from new clients but also generates additional revenues from existing clients by exposing them to additional products or larger populations. The B2B2C channel is contributing more than 70% of our revenues as of the first quarter of 2024, and we expect it to continue growing as a result of such contracts."
This is Dario’s latest announcement for Twill. In September, the company announced that it had integrated Twill with cardiometabolic health solutions.2
In a press release issued at the time, Dario’s chief product officer Keren Zimmerman said, “There is no single standard of care for every chronic health condition that will work across the diversity of members on Dario's platform. That's why we are constantly assessing clinical evidence and behavioral engagement data to continuously enhance the way we support our members. The new enhancements provide an element that many people need in order to achieve better results. Integrating these capabilities into the Dario platform is just the first step in driving a deeper, more effective approach to health management as we aim to build out the market's most holistic, consumer-centric digital health platform.”
In the same press release, Nelson added, “One common theme we hear in the market is the need for better adoption of digital health. We believe that our ability to leverage unique social and community capabilities from Twill by Dario will assist us in creating one of the most comprehensive engagement platforms in the market. Combined with our proven approach to chronic condition management, we believe that we are able to offer an unparalleled ability to engage the right members at the right time for maximum, sustainable impact.”
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.